Abstract: The present invention provides methods and compositions for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of microorganisms including bacteria, bacterial spores, fungi, fungal spores and enveloped viruses.

Abstract: Disclosed is a method for preparing sustained release microparticles which release a physiologically active substance for long periods of time. The sustained release microparticles are prepared through a multi-emulsion process. A drug of interest is dissolved or dispersed in each of at least two oils to give at least two primary oil phases or emulsions. Each oil phase or emulsion contains a biodegradable polymer. The least two primary oil phases or emulsions are dispersed in one aqueous phase, synchronously or in succession. From the drug-dispersed solution, the organic solvents are removed to produce microparticles. Therefore, the drugs such as leutenizing hormone releasing hormones can be continuously released in vivo for prolonged periods of time, bringing about an improvement in the therapeutic effect.

Abstract: A range of products and methods are based on a creamy base of cream, artificial cream, thickened cream, cream cheese, mixtures thereof and mixtures with compatible incidental ingredients, the creamy base being aerated while cold and intimately mixed with a hot aqueous gelatin solution typically around 80° C. and providing 1-3% gelatin in the mixed product and the overrun in the aeration being typically in the range of 10-40%. Various further components are included or introduced with further processing selected from methods including heating the product with a further component to boiling point whereby de-aeration and enhanced shelf life is found in the resultant product. An alternative method is where flavor components are added prior to de-aeration. Another application is as a carrier for a pharmaceutical agent which is incorporated into the creamy base and protected with the gelatin matrix, a powder being formed ready for packaging in pharmaceutical doses.

Abstract: The present invention relates to oil-in-water mascara compositions comprising water-insoluble polymeric materials in the form of an aqueous emulsion, water-soluble, film-forming polymers and organophilic clays. Said compositions exhibit improved wear and are removable with soap and water.

Abstract: A dermatic cosmetic material containing as a substrate a silicone composition paste comprising (i) a cross-linked silicone polymer having hydrophilic polyoxyalkylene groups wherein polyoxyethylene moieties are comprised, which functions as a thickener component, and (ii) a silicone oil, thereby enabling stable incorporation of an antiperspirant or water-soluble vitamins and further ensuring improvements in usability.

Abstract: Low-viscosity cosmetic or dermatological preparations comprising (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid, (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms, (III) a water phase, (IV) from 0 to 10% by weight of a lipid phase, based on the total weight of the preparations, where the weight ratio of the sum of the constituents from (I) and (I): (IV) is chosen from the range from 20:1 to 1:5.

Abstract: A non-sticky, clear water-in-oil emulsion comprising: (a) 65-90 weight % of an internal phase comprising 5-35 weight % of an antiperspirant salt (anhydrous basis) having a metal:chloride ratio in the range of 0.9-1.4:1; 5-15 weight % of tripropylene glycol; and 35-70 weight % water; and (b) 10-35 weight % of an external phase comprising 1-40 weight % of a volatile silicone which is not an elastomer; 0.1-5 weight % of a silicone copolyol surfactant; and 0-20 weight % of a nonvolatile silicone which is not an elastomer; wherein the composition is free of (1) C1-5 saturated alcohols, (2) added propylene glycol, (3) elastomer gelling agents, (4) soap gelling agents (5) borate gelling agents, and (6) coupling agents, and wherein all amounts are in % by weight based on the total weight of the composition.

Abstract: Detergent and conditioning compositions having a washing base and a conditioning system with an oil nanoemulsion.

Abstract: A composition in the form of an oil-in-water (o/w) emulsion containing an oily phase dispersed in an aqueous phase, which contains a mixture of nonionic emulsifiers, the mixture being liquid at ambient temperature and having an HLB ranging from about 6 to 13, and in that the oily phase comprises at least about 5% by weight of one or more waxes based on the total weight of the composition, at least one of the waxes having a starting melting temperature of greater than or equal to about 50° C.

Abstract: The present invention relates to novel stable <<water-in-oil>> emulsions containing 5 to 70% by weight of an aqueous phase 20 to 90% by weight of a fatty phase; and 3 to 25% by weight of an emulsifier comprising 10 to 90% by weight, preferably 10 to 50% by weight and more preferably 10 to 40% by weight of a mixture in any proportion of an oleyl glycoside having a degree of polymerisation of between 1 and 3 and an isostearyl glycoside having a degree of polymerisation of between 1 and 3; and 90 to 10% by weight, preferably 90 to 50% by weight, and more preferably 90 to 60% by weight of a mixture in any proportion of oleyl alcohol and isostearyl alcohol and optionally 0 to 10% by weight of a co-emulsifier; 0 to 10% by weight of a stabiliser. Application: Cosmetic industry.

Abstract: Disclosed are skin care compositions that are emulsion formulations comprising an aqueous phase, an oil phase, at least one emulsifier, and an epichlorohydrin cross-linked glyceryl starch.

Abstract: The invention relates to new cosmetic and/or pharmaceutical formulations containing (a) dialkyl carbonates corresponding to formula (I): in which R1 is a linear alkyl and/or alkenyl group containing 6 to 22 carbon atoms, a 2-ethylhexyl, isotridecyl or isostearyl group or a group derived from a polyol containing 2 to 15 carbon atoms and at least two hydroxyl groups, R2 has the same meaning as R1 or is an alkyl group containing 1 to 5 carbon atoms and n and m independently of one another stand for 0 or numbers of 1 to 100, and (b) emulsifiers. The formulations are distinguished by particular sensorial properties, the dialkyl carbonates proving to be as effective as the silicone oils which they are intended to replace.

Abstract: A method for producing aqueous emulsions or suspensions is described, in which a liquid phase is added to a supply tank, which is connected to a homogenizer having a stator, a rotor mounted rotatably in the stator and an additional connection, through which a second phase, which is to be homogenized, can be added directly onto the rotor and comes into contact with the previously added phase only in the toothed rings of the rotor, the homogenizer is started and subsequently the second phase, which is insoluble in the previously added phase and is to be homogenized, is supplied in liquid form through the additional connection. At least one of the two phases is an aqueous phase and at least one of the two phases is not heated.

Abstract: Tocol-based compositions of charged amphiphilic and water soluble pharmaceutically active compounds or their charged precursors are prepared by forming a tocol-soluble ion pair with an oppositely charged ion-pair forming compound capable of forming a tocol-soluble ion-pair with the active compound. Also disclosed are novel compounds tocopherolsuccinate-aspartate and tocopherolsuccinate-glutamate, which are useful as ion-pair forming compounds.

Abstract: Disclosed is an infusion preparation for nutrient supply use. It comprises a sugar, amino acids, electrolytes and a fat emulsion. It has an excellent shelf life without causing precipitation, denaturation and the like in spite of the simultaneous presence of these components. Also disclosed is a container filled with infusion liquids comprising a first and a second compartment separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment. Further disclosed are an infusion preparation comprising a fat emulsion and a sugar, and an infusion preparation comprising amino acids and electrolytes.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: The present invention relates to the use of a composition comprising: 10 to 90% by weight, preferably 10 to 50% by weight and particularly preferably 10 to 40% by weight of an isostearyl glycoside with a degree of polymerization of between 1 and 3; and 90 to 10% by weight, preferably 90 to 50% by weight and particularly preferably 90 to 60% by weight of isostearyl alcohol as an agent for improving the water resistance of a cosmetic composition.

Abstract: A nanoemulsion comprising an oily phase dispersed in an aqueous phase and having oil globules with a number-average size of less than 100 mm, which dispersion is facilitated by a surfactant comprised of polyethylene oxide and polypropylene oxide blocks, the oily phase comprising at least one oil having a molecular weight of greater than 400 and wherein the ratio by weight of the amount of oily phase to the amount of surfactant ranges from 2 to 10.

Abstract: Disclosed are sunscreen compositions comprising zinc oxide and at least one of an effective amount of carbomer and an effective amount of C10 to C30 alkyl acrylate crosspolymers. The compositions most preferably utilize an oil in water emulsion. Also disclosed are related processes for producing and using such compositions.

Abstract: Skin care compositions comprising an oil-in-water emulsion base containing retinoids and possessing good physical and chemical stability.

Abstract: A nanoemulsion, the oil globules of which have an average size of less than 100 nm, comprising a surfactant chosen from the alkoxylated alkenyl succinates, the alkoxylated alkenyl succinates of glucose and the alkoxylated alkenyl succinates of methylglucose, and at least one oil having a molecular weight of greater than 400, the ratio by weight of the amount of oily phase to the amount of surfactant ranging from 2 to 10. The emulsion obtained is transparent and stable on storage. It can comprise large amounts of oil while retaining good transparency and while having good cosmetic properties. It can constitute a composition for topical use, a pharmaceutical composition or an ophthalmological composition.

Abstract: A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as low molecular weight heparin, are provided. The dosage form comprises a composition of: (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and a means for delaying release of the composition from the dosage form following oral administration. Osmotic drug delivery systems for oral administration of a hydrophilic drug are also provided, wherein an osmotically activated device houses the drug, a bile salt or bile acid, and at least one surfactant selected from the group consisting of hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Methods for administering hydrophilic drugs, particularly polysaccharide drugs such as low molecular weight heparin, are also provided.

Abstract: An emulsion of &agr;-tocopherol, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated &agr;-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of &agr;-tocopherol.

Abstract: An anti-microbial composition comprising (i) an anti-microbial agent, (ii) a polar solvent and (iii) a surface orienting species, which orients anti-microbial agent at a surface of the composition, whereby substantially to prevent the formation of microbial colonies on or at the said surface.

Abstract: The invention relates to an active ingredient combination containing erythrulose and a further reducing sugar with self-tanning properties, for example, dihydroxyacetone, which combination is used for artificially tanning the skin. Compared with compounds containing, for example, only dihydroxyacetone, said active ingredient combination and cosmetic compounds based thereon result in an even and longer-lasting colouring of the skin and prevent skin dehydration and uneven flaking.

Abstract: A pigmented emulsion cosmetic composition for reducing the shiny appearance of skin and cosmetically improving the appearance of skin imperfections comprising a cosmetically effective amount of mushroom extract and a method for reducing the shiny appearance of skin and cosmetically improving the appearance of skin imperfections comprising applying to the skin an emulsion cosmetic composition containing mushroom extract.

Abstract: Cosmetic skin compositions containing a dextran or maltodextrin and a weak carboxylic acid. Dextran enhances the anti-aging activity of the weak acids and reduces skin irritation that is sometimes caused by the weak acid active.

Abstract: The present invention relates to a cosmetic composition comprising (i) a compound selected from the group consisting of creatine, carnitine, and pyruvic acid, and a cosmetically acceptable salt or ester thereof, (ii) a nutrient, and (iii) a skin-conditioning agent selected from the group consisting of an emollient and a humectant.

Abstract: An O/W emulsion composition comprising fluorometholone or clobetasone butyrate, a phospholipid, an oil, a nonionic water-soluble cellulose derivative, and water. The O/W composition has advantages that fluorometholone or clobetasone butyrate contained therein is highly bioavailable and that the solubility of fluorometholone or clobetasone butyrate and the concentration thereof present in the composition can be kept stable. Thus, this composition is usable for the treatment of various inflammatory diseases by the generalized or local administration thereof. It provides a drug which shows an anti-inflammatory activity equal or higher than that of commercially available eye drops comprising a suspension of such an active ingredient even when it is applied in a smaller dose than that of commercially available one and further provides a drug having excellent storability, which reduces apprehension of systemic side effects of fluorometholone or clobetasone butyrate when it is applied to the eyes.

Abstract: Pickering emulsions, which are finely disperse systems of the water-in-oil or oil-in-water type, comprising (1) an oil phase, (2) a water phase, (3) microfine metal oxide particles, a) have an average particle size of less than 200 nm, which b) display both hydrophilic and lipophilic properties, and are dispersible both in water and in oil and which c) have optionally been coated on the surface, (4) at least one cyclodextrin and (5) at most 0.5% by weight of one or more emulsifiers.

Abstract: A method of inhibiting carcinogen mediated conversion of melanocyte cells and protecting DNA against carcinogen-mediated damage by administering a composition comprising a water insoluble carotenoid such as beta-carotene is disclosed.

Abstract: The present invention relates to a stable water-in-oil emulsion for cosmetic, pharmaceutical or hygiene use, comprising an aqueous phase and a fatty phase comprising a silicone oil, characterized in that it comprises an emulsifying system comprising at least one &agr;,&ohgr;-substituted oxyalkylenated silicone of formula (I): in which: R=—(CH2)pO—(C2H4O)x(C3H6O)yR1 where: R1 represents H, CH3 or CH2CH3, p is an integer ranging from 1 to 5, x ranges from 1 to 100 and y ranges from 1 to 50, it being possible for the units (C2H4O) and (C3H6O) to be distributed randomly or in blocks, the R2 radicals represent a C1-C3 alkyl radical or a phenyl radical, 5≦m≦300, and a co-surfactant chosen from the family of glycol mono- and/or diesters and glyceryl mono-, di- and/or triesters, and mixtures thereof. The invention also relates to a composition comprising the above emulsion, and to its applications in the cosmetics, pharmaceutical, dermatological or hygiene fields.

Abstract: The present invention relates to compositions containing a liquid crystal/gel network (LCGN) emulsion thickened with suitable thickening agents containing oil controlling agents.

Abstract: A nanoemulsion, the oil globules of which have a number-average size of less than 100 nm, comprising a surfactant chosen from mixed esters of a fatty acid or of a fatty alcohol, of a carboxylic acid and of glycerol and at least one oil having a molecular weight of greater than 400, the ratio by weight of the amount of oily phase to the amount of surfactant ranging from 2 to 10. The nanoemulsion may be used in, for example, the cosmetics and dermatological fields, in particular for moisturizing the skin and/or mucous membranes, as well as for treating the hair, and in the ophthalmological field, as an eye lotion for treating the eyes.

Abstract: A moisturizing composition comprising a trihydric or more water soluble polyhydric alcohol, lecithin and 3-methyl-1,3-butylene glycol, wherein lecithin: the trihydric or more water soluble polyhydric alcohol+3-methyl-1,3-butylene glycol=1:1,000 to 1:1 (weight ratio) and the trihydric or more water soluble polyhydric alcohol:3-methyl-1,3-butylene glycol=1:10 to 20:1 (weight ratio), various bases containing the moisturizing composition, and a cosmetic or external preparation containing the moisturizing composition. The moisturizing composition, bases, and cosmetic and external preparation are excellent in moisturizing properties, and have good stability.

Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: Macromolecular drug complexes containing a drug, like human growth hormone, and a polymer having a plurality of acid moieties, like carboxyl moieties or phosphonic acid moieties, and compositions containing the same, are disclosed. Compositions, particularly microemulsions, containing the macromolecular complexes are administered to individuals suffering from a disease or condition, and the complexes release the drug, in vivo, to treat the disease or condition, and to reduce, eliminate, or reverse complications associated with the disease.

Abstract: A composition for topical application to the skin, contains an active principle with irritant character in a cosmetically or pharmaceutically acceptable vehicle, in which the vehicle contains more than 5% by weight of peroxidized vegetable oil having a peroxidation level of between 5 and 600 milliequivalents per kg. The presence of the peroxidized oil reduces the irritant character of the principle, particularly capsaicin and retinoic acid.

Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

Abstract: A nanoemulsion, the oil globules of which have an average size of less than 100 nm, comprising an anionic surfactant chosen from alkyl ether citrates and at least one oil having a molecular weight of greater than 400, the ratio by weight of the amount of oily phase to the amount of surfactant ranging from 2 to 10. The emulsion obtained is transparent and stable on storage. It can comprise large amounts of oil while retaining good transparency and while having good cosmetic properties. It can constitute a composition for topical use, a pharmaceutical composition or an ophthalmological composition. The invention also relates to the use of the nanoemulsion according to the invention in the cosmetics and dermatological fields, in particular for moisturizing the skin and/or mucous membranes, as well as for treating the hair, and in the ophthalmological field, as an eye lotion for treating the eyes.

Abstract: This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

Abstract: A topical composition with silicone oil emulsified in water. The topical composition may be made by diluting a concentrated silicone oil-in-water emulsion with water. The silicone oil of the topical composition and of the concentrated silicone oil-in-water emulsion is suspended in the water by one or more non-ionic surfactants. A combination of non-ionic surfactants may be employed. The topical composition may also include a blend of preservatives, which may be selected to have a synergistic effect. The silicone oil constitutes about 35% of the weight of the concentrated silicone oil-in-water emulsion. The non-ionic surfactant or surfactants make up about 3.5% of the weight of the concentrated oil-in-water emulsion. The diluted topical composition may contain silicone oil in amounts of about 0.1 to about 35%, preferably less than 3% down to about 1%, and more preferably about 1 to about 2% of the weight of the topical composition.

Abstract: A sterile, stable pharmaceutical formulations of oil-in-water emulsions of Propofol containing no preservative are provided that comprise optimal amounts of egg lecithin and soybean oil, with a suitable pH range to prevent significant growth of microorganisms for at least 24 hours after adventitious, extrinsic contamination. The lower pH in the formulation has shown the most antimicrobial activity. The reduced amount of fat in the formulation also allows chronic sedation over extended periods of time with a reduced chance of fat overload in the blood.

Abstract: A composition, in particular a cosmetic composition, which may be in the form of an emulsion, the said composition comprising a specific copolymer comprised of monoolefinically unsaturated C3-C6 carboxylic acid monomer and fatty-chain monomeric ester of acrylic acid. The invention also relates to the use of the said copolymer in cosmetics, in particular for improving the staying power of the composition.

Abstract: Cosmetic skin care compositions containing pulegone. The inventive compositions improve transglutaminase-1 expression and ceramide expression, and enhance the cell uptake of glucose.

Abstract: Cosmetic and dermatological emulsions having at least one aqueous phase, comprising (a) an effective amount of one or more interface-active substances, selected from the group consisting of alkyl glucosides, which are characterized by the structural formula  in which R is a branched or unbranched alkyl radical having from 4 to 24 carbon atoms, (b) where in at least one of the aqueous phases one or more electrolytes is present in dissolved form, the ionic strength of the aqueous phases in which the electrolyte(s) is/are present in dissolved form being at least 0.075 mol/l, (c) and where {overscore (DP)} is an average degree of glucosylation of up to 2.

Abstract: A medical lubricant suitable for injection into the blood stream of a patient. The lubricant is suitable for use with rotating equipment such as atherectomy drive shafts moving within sheaths and over guide wires and other minimally invasive medical devices introduced into a patient through a catheter like instrument. The lubricant is an oil-in-water emulsion including a surfactant, a co-surfactant, and a pH buffer. The lubricant can further include a cryogenic agent and a pH adjusting agent. One lubricant includes olive oil as an emulsified oil, egg yolk phospholipid as a surfactant, sodium deoxycholate as a co-surfactant, glycerin as a cryogenic agent, L-histidine as a pH buffer, and is pH adjusted using sodium hydroxide. The lubricant also includes a therapeutic agent. The lubricant can withstand freeze/thaw cycles as well as saline dilution, heating, and shear stress without significant creaming, separation, or unacceptable increases in oil droplet size.

Abstract: Disclosed are skin care compositions that are emulsion formulations comprising an aqueous phase, an oil phase, at least one emulsifier, and an epichlorohydrin cross-linked glyceryl starch.